The pulmonary route has recently attracted attention as a noninvasive administration route for peptide and protein drugs, and an insulin powder for inhalation was approved by authorities in Europe and the USA. The present study examined usefulness of insulin and gene powders for systemic and local inhalation therapy. We prepared several dry insulin powders by spray drying to examine the eŠect of additives on insulin absorption. Citric acid appears to be a safe and potent absorption enhancer for insulin in dry powder. However, in the powder with citric acid (MIC0.2 SD) insulin was unstable compared with the other powders examined. To improve insulin stability, a combination of insulin powder and citric acid powder was prepared (MIC Mix). MIC Mix showed hypoglycemic activity comparable to MIC0.2 SD while the insulin stability was much better than that of MIC SD. Next, dry insulin powders with mannitol were prepared with supercritical carbon dioxide (SCF); the powder thus prepared reduced blood glucose level rapidly and was more eŠec-tive than that prepared by spray drying. Chitosan-pDNA complex powders as a pulmonary gene delivery system were also prepared with SCF and their in vivo activity was evaluated. The addition of chitosan suppressed the degradation of pCMV-Luc during preparation and increased the storage stability. The luciferase activity in mouse lung was evaluated after pulmonary administration of the powders. The chitosan-pDNA powder with an N/P ratio＝5 increased the luciferase activity to 27 times that of the pCMV-Luc solution. These results suggest that gene powder with chitosan is a useful pulmonary gene delivery system.
The powders taken in a disposable tip was dispersed in the rat trachea by releasing 1-ml air compressed in a syringe by opening a three-way stopcock connecting the tip and the syringe. The plasma glucose levels were determined with time and the area under the curve (AUC) was calculated. The stability samples were assayed at 0, 1, 2, 3, 5, and 10 days after placing them in a stability chamber at 60°C/dry or 25, 50, and 75％ relative humidity. The solution of pCMV-Luc powders containing 0.06 mg of pCMV-Luc was loaded on a 0.6％ agarose gel containing ethidium-bromide. Electrophoresis was carried out with a current of 100 V for 2 h in TAE running buŠer. 
